A Study of the Efficacy and Safety of Ocrelizumab in Patients With Relapsing-Remitting Multiple Sclerosis

Clinical trial NCT00676715 · COMPLETED

Trial details

NCT number: NCT00676715
Sponsor: Genentech, Inc.
Status: COMPLETED
Phase: Phase 2
Study type: INTERVENTIONAL

Multiple Sclerosis, Relapsing-Remitting

Start date: 2008-07-17
Primary completion: 2012-03-09
Enrollment: 220

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.